Please login to the form below

Not currently logged in
Email:
Password:

chronic diseases

This page shows the latest chronic diseases news and features for those working in and with pharma, biotech and healthcare.

The Midas Touch

The Midas Touch

So too is the push towards business models that create value beyond the pill, as we are beginning to see in chronic diseases like asthma and diabetes.

Latest news

More from news
Approximately 2 fully matching, plus 159 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 2 fully matching, plus 42 partially matching documents found.

Latest appointments

  • Kymab appoints its first chief medical officer Kymab appoints its first chief medical officer

    She has over 20 years of experience biomedical research and has focused on pathogenic mechanisms, underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.

  • Dr Li Zhou joins TxCell as cell engineering VP Dr Li Zhou joins TxCell as cell engineering VP

    Dr Zhou will lead the team's discovery and engineering activities on Chimeric Antigen Receptor in Treg cells ( CAR-Treg) for immunotherapy of severe chronic autoimmune and inflammatory diseases and organ

  • Sanofi’s US pharma head joins Synta as CEO Sanofi’s US pharma head joins Synta as CEO

    She now leads an emerging US-based biopharma focused on the development of small molecule drugs to treat patients with severe medical conditions, including cancer and chronic inflammatory diseases.

  • Medgenics confirms appointment of Dr Marvin Garovoy

    The company's Biopump uses a patient's own tissue to continuously produce and deliver their protein therapy and, potentially, has applications in a range of chronic diseases, including diabetes, multiple

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Irritable Bowel Syndrome (IBS) Patient Insights

    However, as is the case with many chronic diseases the extent to which the disease impacts upon a patient’s quality of life is inadequately represented by considering the symptoms alone. ... 2)  . "IBS is a chronic medical condition, although the

  • Wearables and Healthcare

    mid-twenties.[2]  . Factors such as these, among others, have increased the prevalence of chronic diseases, which account for around 70% of the health service budget.[3, 4] To ensure the ... The outputs of this process are predictive algorithms that

  • Aubrey De Grey provides a summary of his goal of combating ageing

    He discusses the fact that many diseases including chronic cancer, are the result of ageing and that by tackling ageing of cells, we can address many of the issues associated with

  • Biosimilars: Getting the flock to market

    Currently, more than 700 biosimilars are being developed around the world, with the focus on chronic diseases and oncology.

  • How can pharma engage with Accountable Care Systems?

    s ageing population and the associated burden of chronic diseases.  . ... In order to engage with ACSs, pharma needs to define how its products can help to prevent diseases and disease progression, and how they can add value across the whole patient

More from PMHub
Approximately 4 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics